Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.
Multiple Myeloma
DRUG: lenalidomide|DRUG: Subcutaneous bortezomib|DRUG: Dexamethasone
To evaluate the overall response rate (ORR) after 4 induction cycles, To evaluate the overall response rate (ORR) after 4 induction cycles and the best response to induction therapy with the combination of lenalidomide, subcutaneous (SQ) bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma., After 4 cycles (84 days)
a) To evaluate the rate and severity of Peripheral Neuropathy (PN) of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy., Evaluate the rate and severity of Peripheral Neuropathy of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy, After 4 cycles (84 days)|Progression of disease, Evaluate the time to progression, Duration of the study, expected to be approximately 3 years|Progression free survival, Evaluate progression free survival, Duration of the study, expected to be approximately 3 years|Duration of response, Duration of the study, expected to be approximately 3 years
This study aims to evaluate the overall response rate after 4 cycles and the best response to induction therapy with combination of lenalidomide, subcutaneous bortezomib, and dexamethasone (RsqVD) in patients with newly diagnosed multiple myeloma.